Drug metabolism in older people - A key consideration in achieving optimal outcomes with medicines

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 67 A, Issue 2, 2012, Pages 175-180

  McLachlan, Andrew J ^a,b   Pont, Lisa G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Drug metabolism; Frailty; Genetics; Hepatic clearance; Pseudocapillarization

Indexed keywords

DRUG;

AGED; AGING; DRUG EFFECT; HUMAN; LIVER; METABOLISM; PHYSIOLOGY; REVIEW; TISSUE DISTRIBUTION;

AGED; AGING; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84856186710     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glr118     Document Type: Review

References (49)

1. McLachlan AJ, Hilmer SN, Le Couteur DG. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin Pharmacol Ther. 2009;85:431-433.
2. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21:217-230. (Pubitemid 46804936)
3. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
4. Hilmer SN, Shenfield GM, Le Couteur DG. Clinical implications of changes in hepatic drug metabolism in older people. Ther Clin Risk Manag. 2005;1:151-156.
5. Fraser R, Dobbs BR, Rogers GT. Lipoproteins and the liver sieve: the role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis. Hepatology. 1995;21:863-874.
6. Le Couteur DG, Fraser R, Hilmer SN, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet. 2005;44:187-200. (Pubitemid 40188940)
7. Hilmer SN, Cogger VC, Fraser R, McLean AJ, Sullivan D, Le Couteur DG. Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat. Hepatology. 2005;42:1349-1354. (Pubitemid 43260037)
8. Le Couteur DG, Cogger VC, Markus AMA, Harvey PJ, Yin Z-L, Ansselin AD, McLean AJ. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology. 2001;33:537-543. (Pubitemid 32185214)
9. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev. 2004;56:163-184. (Pubitemid 38720828)
10. Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet. 1988;15:287-294.
11. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008;47:297-321. (Pubitemid 351508117)
12. Wilkinson GR. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev. 1997;27:129-159. (Pubitemid 27417870)
13. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-339. (Pubitemid 27145435)
14. Wynne H. Drug metabolism and ageing. J Br Menopause Soc. 2005;11:51-56. (Pubitemid 40872876)
15. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging. 2001;18:837-851. (Pubitemid 34073129)
16. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76.
17. Wright DF, Begg EJ. The 'apparent clearance' of free phenytoin in elderly vs. younger adults. Br J Clin Pharmacol. 2010;70:132-138.
18. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193-209.
19. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev. 2010;42:209-224.
20. Wynne HA, Cope LH, Herd B, Rawlins MD, James OF, Woodhouse KW. The association of age and frailty with paracetamol conjugation in man. Age Ageing. 1990;19:419-424.
21. Wynne HA, Yelland C, Cope LH, Boddy A, Woodhouse KW, Bateman DN. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing. 1993;22:354-359. (Pubitemid 23282362)
22. Hilmer SN, Cogger VC, Muller M, Le Couteur DG. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos. 2004;32:794-799. (Pubitemid 38955607)
23. Hong Y, Ramzan I, McLachlan AJ. Hepatobiliary disposition of liposomal amphotericin B in the isolated perfused rat liver. J Pharm Sci. 2004;94:169-176.
24. Simon-Santamaria J, Malovic I, Warren A, et al. Age-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cells. J Gerontol A Biol Sci Med Sci. 2010;65A:951-960.
25. Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M, Roberts MS. Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther. 2002;301:1079-1087. (Pubitemid 34595100)
26. Mitchell SJ, Huizer-Pajkos A, Cogger VC, et al. Age-related pseudocapillarization of the liver sinusoidal endothelium impairs the hepatic clearance of acetaminophen in rats. J Gerontol A Biol Sci Med Sci. 2011;66:400-408.
27. Mitchell SJ, Huizer-Pajkos A, Cogger VC, McLachlan AJ, Couteur DGL, Hilmer SN. Poloxamer 407 increases the recovery of paracetamol in the isolated perfused rat liver. J Pharm Sci. 2011;100:334-340.
28. Fried LP, Tangen CM, Walston J. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-M156.
29. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc. 2006;54:991-1001. (Pubitemid 43847040)
30. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol. 2008;64:895-900.
31. Schwartz JB. Erythromycin breath test results in elderly, very elderly, and frail elderly persons. Clin Pharmacol Ther. 2006;79:440-448.
32. de Vries NM, Staal JB, van Ravensberg CD, Hobbelen JSM, Olde Rikkert MGM, Nijhuis-van der Sanden MWG. Outcome instruments to measure frailty: a systematic review. Ageing Res Rev. 2011;10:104-114.
33. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. Sci World J. 2001;1:323-336.
34. Rolfson DBM. Validity and reliability of the Edmonton Frail Scale. Age Ageing. 2006;35:526-529.
35. Hilmer SN, Perera V, Mitchell S, et al. The assessment of frailty in older people in acute care. Aust J Ageing. 2009;28:182-188.
36. Hilmer SN, Tran K, Rubie P, et al. Gentamicin pharmacokinetics in old age and frailty. Br J Clin Pharmacol. 2011;71:224-231.
37. Mitchell SJ, Hilmer SN, Murnion BP, Matthews S. Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. J Clin Pharm Ther. 2011;36:327-335.
38. Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38:156-162.
39. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1:629-640.
40. Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther. 2006;80:228-234. (Pubitemid 44301092)
41. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86-88.
42. Roughead EE, Kalisch LM, Barratt JD, Gilbert AL. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol. 2010;70:252-257.
43. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185-191. (Pubitemid 47042897)
44. Vestal RE, Cusack BJ, Crowley JJ, Loi CM. Aging and the response to inhibition and induction of theophylline metabolism. Exp Gerontol. 1993;28:421-433. (Pubitemid 23226559)
45. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex and rifampicin administration on intestinal and hepatic cytochrome P4503A activity. Clin Pharmacol Ther. 2003;74:275-287. (Pubitemid 37083103)
46. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. The effect of aging on the relationship between the cytochrome P4502C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet. 2005;44:1179-1189. (Pubitemid 41483702)
47. Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U. Influence of age and cytochrome P4502C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet. 2003;42:283-292. (Pubitemid 36308065)
48. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007;63:1135-1141. (Pubitemid 350112769)
49. Gomez A, Ingelman-Sundberg M. Pharmacoepigenetics: its role in interindividual differences in drug response. Clin Pharmacol Ther. 2009;85:426-430.